120 related articles for article (PubMed ID: 22862790)
1. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Srkalovic G; Hussein M
Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide in multiple myeloma-a practice guideline.
Chen C; Baldassarre F; Kanjeekal S; Herst J; Hicks L; Cheung M
Curr Oncol; 2013 Apr; 20(2):e136-49. PubMed ID: 23559881
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
Chen N; Zhou S; Palmisano M
Clin Pharmacokinet; 2017 Feb; 56(2):139-152. PubMed ID: 27351179
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue disposition of lenalidomide in mice.
Rozewski DM; Herman SE; Towns WH; Mahoney E; Stefanovski MR; Shin JD; Yang X; Gao Y; Li X; Jarjoura D; Byrd JC; Johnson AJ; Phelps MA
AAPS J; 2012 Dec; 14(4):872-82. PubMed ID: 22956478
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in myeloma: how far have we come?
Franssen LE; Mutis T; Lokhorst HM; van de Donk NWCJ
Ther Adv Hematol; 2019; 10():2040620718822660. PubMed ID: 30719268
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Ullenhag GJ; Rossmann E; Liljefors M
PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related symptom management in patients with multiple myeloma: a review.
Colson K
Support Care Cancer; 2015 May; 23(5):1431-45. PubMed ID: 25646616
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
11. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Bringhen S; Gay F; Pautasso C; Cerrato C; Boccadoro M; Palumbo A
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1209-22. PubMed ID: 22862790
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
15. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
